DexCom

Update in progress

DXCM (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health worldwide. Its products include Dexcom G7 and G7 15 Day, Dexcom G6, Dexcom ONE+ (to replace fingerstick testing for treatment decisions), Stelo biosensor for adults with prediabetes or Type 2 diabetes, Dexcom Share, and the Dexcom Follow app. The company sells through clinicians and educators and is headquartered in San Diego, founded in 1999.

Company score

Sentiment: 2.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.09; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 2.52; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.40; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.63; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.40; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive